Boston Partners Grows Stake in Lantheus Holdings, Inc. $LNTH

Key Points

• Boston Partners increased its stake in Lantheus Holdings by 10.2% during the first quarter, owning 441,581 shares valued at approximately $43.23 million.
• Numerous institutional investors significantly boosted their holdings in Lantheus, with Janus Henderson Group increasing its position by 72.7% during the last quarter.
• Analysts have mixed opinions on Lantheus, with a current consensus rating of "Moderate Buy" and a revised price target ranging from $63.00 to $109.00.

Boston Partners grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 10.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 441,581 shares of the medical equipment provider's stock after acquiring an additional 40,784 shares during the period. Boston Partners owned about 0.64% of Lantheus worth $43,228,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in LNTH. Russell Investments Group Ltd. lifted its position in shares of Lantheus by 204.8% in the 1st quarter. Russell Investments Group Ltd. now owns 51,682 shares of the medical equipment provider's stock worth $5,044,000 after buying an additional 34,727 shares during the last quarter. Prudential PLC boosted its position in shares of Lantheus by 168.7% in the first quarter. Prudential PLC now owns 36,917 shares of the medical equipment provider's stock worth $3,603,000 after buying an additional 23,180 shares during the period. HighTower Advisors LLC increased its stake in Lantheus by 107.8% in the 1st quarter. HighTower Advisors LLC now owns 4,797 shares of the medical equipment provider's stock valued at $468,000 after buying an additional 2,488 shares during the period. Eagle Global Advisors LLC bought a new position in shares of Lantheus during the 1st quarter valued at $9,290,000. Finally, Nuveen LLC acquired a new stake in shares of Lantheus in the first quarter worth about $55,941,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on LNTH. Mizuho lowered their price target on Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, August 7th. Truist Financial set a $63.00 price objective on Lantheus and gave the stock a "hold" rating in a research note on Monday, August 11th. JMP Securities cut their price objective on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a report on Thursday, August 7th. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, B. Riley cut their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $105.50.

Insider Buying and Selling at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.50% of the stock is owned by corporate insiders.

Lantheus Price Performance

LNTH traded down $0.3570 during midday trading on Tuesday, hitting $55.6130. The stock had a trading volume of 455,286 shares, compared to its average volume of 1,159,404. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The business has a fifty day moving average of $73.29 and a 200 day moving average of $85.13. The company has a market cap of $3.78 billion, a P/E ratio of 14.77 and a beta of 0.14.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $378.05 million for the quarter, compared to analysts' expectations of $389.69 million. During the same quarter in the prior year, the firm earned $1.80 EPS. The firm's revenue for the quarter was down 4.1% on a year-over-year basis. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.